British Columbia Expands Use of Biosimilars to Explore Treatment Options
Shots:
- BC decided to switch from reference product to biosimilars within 6 months- for patients suffering from diabetes- ankylosing spondylitis- plaque psoriasis- psoriatic arthritis- and rheumatoid arthritis
- Post Nov 25-2019 PharmaCare- a publicly funded national drug coverage program will no longer be providing coverage for the biologic products excluding some exceptional cases and patients receiving Enbrel- Remicade and Lantus will switch to Eticovo- Renflexis and Basaglar respectively
- BC plans to save $96.6B in first three years and the decision is in practice with the listing of Jardiance and Taltz drug for diabetes and psoriatic arthritis respectively
Click here to read full press release/ article | Ref: British Columbia | Image: LinkedIn
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com